CN114746063A - Antimicrobial compositions comprising modified clays and copolymers - Google Patents
Antimicrobial compositions comprising modified clays and copolymers Download PDFInfo
- Publication number
- CN114746063A CN114746063A CN202080082792.5A CN202080082792A CN114746063A CN 114746063 A CN114746063 A CN 114746063A CN 202080082792 A CN202080082792 A CN 202080082792A CN 114746063 A CN114746063 A CN 114746063A
- Authority
- CN
- China
- Prior art keywords
- composition
- oral
- antimicrobial
- composition according
- dental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 51
- 229920001577 copolymer Polymers 0.000 title claims abstract description 28
- 239000002245 particle Substances 0.000 claims abstract description 38
- 239000000606 toothpaste Substances 0.000 claims abstract description 14
- 239000004927 clay Substances 0.000 claims description 43
- 239000004599 antimicrobial Substances 0.000 claims description 38
- -1 polyethylene succinate Polymers 0.000 claims description 27
- 150000001768 cations Chemical class 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 18
- 229960001927 cetylpyridinium chloride Drugs 0.000 claims description 16
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 11
- 239000011976 maleic acid Substances 0.000 claims description 11
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 9
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- 210000000214 mouth Anatomy 0.000 claims description 8
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 claims description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 229920001897 terpolymer Polymers 0.000 claims description 7
- 229940034610 toothpaste Drugs 0.000 claims description 7
- 208000006558 Dental Calculus Diseases 0.000 claims description 6
- 208000025157 Oral disease Diseases 0.000 claims description 6
- 208000030194 mouth disease Diseases 0.000 claims description 6
- 239000002324 mouth wash Substances 0.000 claims description 6
- 206010044029 Tooth deposit Diseases 0.000 claims description 5
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 5
- 230000032770 biofilm formation Effects 0.000 claims description 5
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 claims description 5
- 208000002925 dental caries Diseases 0.000 claims description 5
- 239000000551 dentifrice Substances 0.000 claims description 5
- 208000024693 gingival disease Diseases 0.000 claims description 5
- 229940051866 mouthwash Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 5
- 208000002064 Dental Plaque Diseases 0.000 claims description 4
- 229960001950 benzethonium chloride Drugs 0.000 claims description 4
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 4
- 229920000921 polyethylene adipate Polymers 0.000 claims description 4
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 238000002845 discoloration Methods 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 2
- 229960002798 cetrimide Drugs 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 229940041672 oral gel Drugs 0.000 claims description 2
- 229940041678 oral spray Drugs 0.000 claims description 2
- 239000000668 oral spray Substances 0.000 claims description 2
- 239000007935 oral tablet Substances 0.000 claims description 2
- 229940096978 oral tablet Drugs 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- 239000000377 silicon dioxide Substances 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- 239000004094 surface-active agent Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 210000000515 tooth Anatomy 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000008719 thickening Effects 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- 206010006326 Breath odour Diseases 0.000 description 6
- 208000032139 Halitosis Diseases 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003906 humectant Substances 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 6
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 150000002169 ethanolamines Chemical class 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 241000186361 Actinobacteria <class> Species 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000003082 abrasive agent Substances 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 4
- 229910052622 kaolinite Inorganic materials 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 241000555676 Malassezia Species 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 239000003945 anionic surfactant Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 229910001919 chlorite Inorganic materials 0.000 description 3
- 229910052619 chlorite group Inorganic materials 0.000 description 3
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 241000605909 Fusobacterium Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241000555688 Malassezia furfur Species 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- 241000192142 Proteobacteria Species 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 241000193987 Streptococcus sobrinus Species 0.000 description 2
- 241000589886 Treponema Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000003214 anti-biofilm Effects 0.000 description 2
- 230000002272 anti-calculus Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910044991 metal oxide Inorganic materials 0.000 description 2
- 150000004706 metal oxides Chemical class 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 238000004383 yellowing Methods 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VSHIRTNKIXRXMI-UHFFFAOYSA-N 2,2-dimethyl-1,3-oxazolidine Chemical compound CC1(C)NCCO1 VSHIRTNKIXRXMI-UHFFFAOYSA-N 0.000 description 1
- SFKRXQKJTIYUAG-UHFFFAOYSA-N 2,3,4,5-tetrafluorobenzoic acid Chemical compound OC(=O)C1=CC(F)=C(F)C(F)=C1F SFKRXQKJTIYUAG-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- DBHODFSFBXJZNY-UHFFFAOYSA-N 2,4-dichlorobenzyl alcohol Chemical compound OCC1=CC=C(Cl)C=C1Cl DBHODFSFBXJZNY-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- QJGSJXLCJRXTRY-UHFFFAOYSA-N 2-[1-(2-amino-2-oxoethyl)cyclohexyl]acetic acid Chemical compound NC(=O)CC1(CC(O)=O)CCCCC1 QJGSJXLCJRXTRY-UHFFFAOYSA-N 0.000 description 1
- IGYXYGDEYHNFFT-UHFFFAOYSA-N 2-chloro-4-fluorophenol Chemical compound OC1=CC=C(F)C=C1Cl IGYXYGDEYHNFFT-UHFFFAOYSA-N 0.000 description 1
- IBRSSZOHCGUTHI-UHFFFAOYSA-N 2-chloropyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1Cl IBRSSZOHCGUTHI-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000190890 Capnocytophaga Species 0.000 description 1
- 241001496942 Cellulophaga Species 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010022524 Intentional self-injury Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000005560 Self Mutilation Diseases 0.000 description 1
- 239000004965 Silica aerogel Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 208000004509 Tooth Discoloration Diseases 0.000 description 1
- 206010044032 Tooth discolouration Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 241001148134 Veillonella Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Chemical group 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- HPTYUNKZVDYXLP-UHFFFAOYSA-N aluminum;trihydroxy(trihydroxysilyloxy)silane;hydrate Chemical compound O.[Al].[Al].O[Si](O)(O)O[Si](O)(O)O HPTYUNKZVDYXLP-UHFFFAOYSA-N 0.000 description 1
- 229910001588 amesite Inorganic materials 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 229960003887 dichlorophen Drugs 0.000 description 1
- 229910001649 dickite Inorganic materials 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- COMCQVMUJUBJSV-UHFFFAOYSA-M disodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate;phosphinite;prop-2-enoic acid Chemical compound [Na+].[Na+].P[O-].OC(=O)C=C.[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C COMCQVMUJUBJSV-UHFFFAOYSA-M 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000002979 fabric softener Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052621 halloysite Inorganic materials 0.000 description 1
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 1
- 229960004068 hexachlorophene Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229960003258 hexylresorcinol Drugs 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical compound COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 108700019599 monomethylolglycine Proteins 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- XFHJDMUEHUHAJW-UHFFFAOYSA-N n-tert-butylprop-2-enamide Chemical compound CC(C)(C)NC(=O)C=C XFHJDMUEHUHAJW-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- MEUIIHOXOWVKNP-UHFFFAOYSA-N phosphanylformic acid Chemical compound OC(P)=O MEUIIHOXOWVKNP-UHFFFAOYSA-N 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- OIQJEQLSYJSNDS-UHFFFAOYSA-N piroctone Chemical compound CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O OIQJEQLSYJSNDS-UHFFFAOYSA-N 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 229940101011 sodium hydroxymethylglycinate Drugs 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- CITBNDNUEPMTFC-UHFFFAOYSA-M sodium;2-(hydroxymethylamino)acetate Chemical compound [Na+].OCNCC([O-])=O CITBNDNUEPMTFC-UHFFFAOYSA-M 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000007852 tooth bleaching agent Substances 0.000 description 1
- 230000036367 tooth discoloration Effects 0.000 description 1
- 230000036344 tooth staining Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0245—Specific shapes or structures not provided for by any of the groups of A61K8/0241
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
- A61K8/416—Quaternary ammonium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8117—Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8188—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bonds, and at least one being terminated by a bond to sulfur or by a hertocyclic ring containing sulfur; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/85—Polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q15/00—Anti-perspirants or body deodorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Abstract
The present invention is in the field of antimicrobial compositions, for example for personal care. In particular, the present invention relates to antimicrobial compositions for oral care, such as toothpastes, comprising antimicrobial particles and specific copolymers. The invention also relates to uses and methods of the antimicrobial compositions of the invention.
Description
Technical Field
The present invention is in the field of personal care. In particular, the present invention relates to an antimicrobial composition useful, for example, in oral care. The antimicrobial composition comprises a modified clay and a copolymer. The invention also relates to the use of the antimicrobial composition.
Background
Hygiene and proper personal care can prevent and treat a variety of diseases caused by microorganisms. Useful means of promoting and improving hygiene include personal care compositions. The most effective personal care compositions for this purpose include antimicrobial components, which reduce the number of microorganisms on skin and mucosal surfaces. For example, the antimicrobial composition in a deodorant can reduce or prevent the growth of microorganisms that produce malodor or promote the breakdown of body oils into odoriferous fatty acids. Similar principles apply to shampoos, body washes, toothpastes, hand and body washes, and other examples of personal care compositions comprising antimicrobial compositions.
One of the most important aspects of personal care is oral health. Dental caries, dental calculus, gum diseases such as gingivitis, plaque and halitosis are diseases in the oral cavity (or conditions caused by or likely to cause disease) which can be easily prevented or treated by adequate oral hygiene. These diseases and conditions are important not only from a medical point of view, but also from a cosmetic point of view, since they may impair the appearance of a person's smile (such as teeth yellowing or halitosis, which does not necessarily have a pathological origin). In any case, unhealthy and/or impaired oral conditions may affect people's social activities, sometimes resulting in self-mutilation. Despite its relevance to the oral health of human subjects, oral care is also of increasing importance in the veterinary industry, whether for pets or large animals.
Oral diseases and aesthetic oral conditions are caused by the formation of biofilm on the surfaces of teeth. Oral biofilms can affect appearance because they can promote tooth discoloration and/or staining (staining).
Oral biofilms are formed by attaching acquired films, which are protein-containing films derived from salivary glycoproteins, to clean tooth surfaces. The film enables bacteria from so-called pioneer species such as actinomycetes (actinomycetes spp), Streptococcus (Streptococcus spp), Haemophilus (haemapophilus spp), cabnocytophaga (Capnocytophaga spp), veyonia (Veillonella spp) and Neisseria (Neisseria) to adhere to the tooth surface. This early stage of biofilm formation can be easily reversed. However, if not removed, the pioneer bacteria will cause the subsequent attachment of bacterial species such as Fusobacterium nucleatum (Fusobacterium tuberculosis), Treponema spp, danshenna venenatus (tannorella), porphyromonas gingivalis, actinomycetemcomitans (actinomycetemcomitans), etc., which are associated with the formation of dental plaque, tartar, gum disease, etc.
Halitosis can be a symptom of oral disease, as it is often indicative of the presence of pathogens that cause, for example, tooth decay and gingivitis. However, halitosis is not always associated with medical conditions. Halitosis or oral malodor can be caused by, for example, some medications, excessive caffeine intake, or reduced saliva production (dry mouth). Non-pathological oral malodor can be prevented or controlled with oral care compositions such as mouthwashes, chewing gums, toothpastes, breath tablets, and other products that ensure oral cleanliness and provide fresh breath.
A variety of oral care compositions have been proposed, and some have even been marketed to address the above-mentioned problems. Nevertheless, there is still a need for consumers to solve the above problems and they are always looking for solutions that involve little or no actives considered as harsh chemical sources. Thus, compounds that are generally considered inert, such as naturally occurring clays or polymers, whether of natural or synthetic origin, are generally accepted by consumers. The present inventors, in seeking such solutions, have obtained, through the intrinsic knowledge of these materials and through extensive experiments, a combination of a modified clay (which has been patented and published as WO 2011/036031) and a specific copolymer providing a synergistic anti-biofilm efficacy.
WO2011/036031a1 describes a bipolar antimicrobial particle for use in laundry detergent compositions, fabric conditioners, personal care and cosmetic compositions and a method of making the same. The antimicrobial particles described therein comprise modified clay particles having antimicrobial groups attached thereto. The examples describe the preparation of the modified clay particles and their antimicrobial activity, particularly on fabrics.
Oral care compositions comprising the copolymers are also reported. EP0341660(Goodrich,1989) discloses oral compositions and methods for inhibiting dental calculus characterized by the presence of a fluoride source, a dental abrasive and an anticalculus agent of at least two polymers selected from homopolymers of a carboxyl monomer selected from monounsaturated carboxylic acids having from 3 to 5 carbons, anhydrides thereof, salts thereof and mixtures of said carboxyl monomers and copolymers containing at least 30% of said carboxyl monomer.
WO13187918(P & G) discloses a liquid, cleaning and/or rinsing composition comprising biodegradable abrasive cleaning particles comprising biodegradable polyester material selected from a large group of copolymers.
EP0525913(Colgate,1993) discloses a toothpaste or dental gel composition containing an amount of a synthetic linear viscoelastic cross-linked polymeric thickener, especially a cross-linked methyl vinyl ether/maleic anhydride copolymer, effective to impart linear viscoelastic properties to the composition, and a method of promoting oral hygiene by applying an effective amount of the composition to a tooth surface.
Despite the above-disclosed technologies, there remains a need for antimicrobial compositions, particularly compositions for personal care such as oral care, having further improved antimicrobial activity.
Disclosure of Invention
The present inventors have surprisingly found that modified clay particles comprising an antimicrobial component exhibit synergistic antimicrobial activity when used in compositions further comprising selected copolymers.
Accordingly, in a first aspect, the present invention relates to an antimicrobial composition comprising:
a) modified clay particles comprising an antimicrobial compound, the modified clay particles comprising:
(i) asymmetric 1: 1 or 2: 1 clay particles comprising alternating tetrahedral and octahedral sheets terminating at the tetrahedral sheet at one external surface plane and the octahedral sheet at another external surface plane, and
(ii) at least one orally acceptable antimicrobial compound attached to the coordinating cations on the outer surface plane of the clay particles; and
b) a polymer selected from (i) a copolymer of styrene sulfonic acid and maleic acid; (ii) polyethylene succinate; (iii) polyethylene adipate; (iv) a phosphinocarboxylic acid copolymer; or (v) a carboxylate sulfonate terpolymer.
In a second aspect, the present invention relates to a composition of the first aspect for use in the prevention or treatment of a disease in a mammal, preferably for use in the prevention or treatment of an oral disease selected from the group comprising dental caries, dental calculus, dental plaque, gum disease and combinations thereof.
In a third aspect, the present invention is directed to the composition of the first aspect for use in removing oral biofilm from a mammalian subject.
Yet another aspect claims a non-therapeutic method of treating the skin and/or oral cavity of a mammal comprising the step of contacting the skin and/or oral cavity of the mammal with the antimicrobial composition of the first aspect.
Yet another aspect of the present invention relates to the use of the composition of the present invention for reducing body malodor, preferably oral malodor, and/or for reducing oral biofilm formation and/or for reducing dental discoloration in a mammal.
Detailed Description
Modified particles
The composition according to the invention comprises modified clay particles comprising the antimicrobial compound, the modified clay particles comprising asymmetric 1: 1 or 2: 1 clay particles having alternating tetrahedral and octahedral sheets terminating at the external surface plane in tetrahedral and octahedral sheets. Preferably 1: 1 clay particles.
The particles are prepared from precursors having bipolar topospecific (topospecific) characteristics. Any chemical reaction or series of reactions in which an antimicrobial compound is selectively attached to coordinating cations on the outer surface of the tetrahedral or octahedral surface plane of an asymmetric clay can be used to prepare the bipolar particles comprising an antimicrobial compound for use in the present invention. In order to obtain truly bipolar antimicrobial particles, it is preferred that the reaction be selective to only one external plane. Selectivity means that more than 50% of the total antimicrobial compounds are present on one of the external planes, preferably more than 75%, more preferably more than 80%, still more preferably more than 90%, even more preferably more than 95%, or even more than 99%. Bipolar particles comprising antimicrobial compounds for use in compositions according to the invention may be prepared, for example, by the method described in WO2011/036031, which is incorporated herein by reference.
Preferred 1: 1 clays according to the invention include kaolinite and serpentine subfamily minerals. Classes included within the kaolinite subfamily include, but are not limited to, kaolinite, dickite, halloysite, and nacrite. Species within the serpentine subfamily include, but are not limited to, chrysolite, lisianite, and amesite.
Preferred 2: 1 clays according to the invention include the chlorite family of minerals. Some mineralogists sometimes refer to chlorite mistakes as 2: 2 clay. Chlorite consists of tetrahedral-octahedral-tetrahedral sheets, such as 2: 1 clay, with additional weakly bonded brucite-like layers between the tetrahedral layers.
The tetrahedral sheet preferably comprises coordinating tetrahedral cations of silicon. The tetrahedral sheet may also contain isomorphously substituted coordinating tetrahedral cations that are not silicon. Isomorphously (isomorphously) substituted coordinating tetrahedral cations include, but are not limited to, aluminum, iron, or boron cations.
The octahedral sheets preferably contain coordinated octahedral cations of aluminum. The octahedral sheets may also contain isomorphously substituted coordinating octahedral cations that are not aluminum. Isomorphously substituted coordinated octahedral cations include cations of magnesium or iron.
The at least one antimicrobial compound is attached to coordinating cations on the outer surface plane of the clay particles. Preferably, no antimicrobial compound is associated with the coordinating cations on the inside of the non-external tetrahedral or octahedral plane or surface sheet.
The antimicrobial compound may be linked to a coordinating cation on the outside of a tetrahedral sheet or a coordinating cation on the outside of an octahedral sheet. Preferably, the at least one antimicrobial compound is linked to coordinating cations on the external surface of the octahedral surface plane.
The at least one antimicrobial compound may be linked to coordinating cations on the outside of the same surface sheet or on the outside of each of tetrahedral and octahedral surface sheets. The antimicrobial compounds may be the same or different. Preferably, the antimicrobial compound of the coordinating cations attached to the outer side of the tetrahedral surface sheet is preferably different from the compound of the coordinating cations attached to the outer side of the octahedral surface sheet.
Preferably, the modified clay particles have a clay to antimicrobial compound weight ratio of from 1: 0.001 to 1: 0.1, more preferably from 1: 0.01 to 1: 0.05, most preferably from about 1: 0.018.
Antimicrobial compounds
The antimicrobial compound is preferably selected from the group consisting of quaternary ammonium material, preferably a salt, an antimicrobial alcohol, an antimicrobial phenol, an antimicrobial organic acid/salt, or combinations thereof.
Preferred antimicrobial alcohols include, but are not limited to, phenoxyethanol, benzyl alcohol, dichlorobenzyl alcohol, dimethyl oxazolidine, DMDM hydantoin, 2-bromo-2-nitropropane-1, 3-diol, diazolidinyl urea, hexachlorophene.
Preferred antimicrobial phenols include, for example, triclosan, thymol, dichlorophen, 2-chloro-4-fluorophenol, tetrafluorobenzoic acid, cresol, hexylresorcinol, microlactones (microcrolides), and the like.
Preferred antimicrobial organic acids/salts are selected from the group consisting of benzoic acid/sodium benzoate, salicylic acid/sodium salicylate, sorbic acid/potassium sorbate, sodium hydroxymethylglycinate, cyclohexanediacetic acid monoamide, chloronicotinic acid, succinic acid, peracetic acid or zinc pyrithione, ketoconazole, piroctone olamine
Or a combination thereof.
Preferred quaternary ammonium substances or salts are selected from the group consisting of cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC), benzethonium chloride (BZC), cetrimide, polyhexamethylene BH, and the like. Even more preferred quaternary ammonium salts are selected from the group consisting of CPC, CTAC, CTAB, BKC or BZC.
In a preferred embodiment, the at least one antimicrobial compound is a quaternary ammonium salt, more preferably, the at least one antimicrobial compound is cetylpyridinium chloride (CPC).
The concentration of the antimicrobial compound in the antimicrobial composition may depend on the use of the composition. Accordingly, in some embodiments, the antimicrobial composition may comprise modified clay particles comprising a therapeutically effective amount of an antimicrobial compound. In another embodiment, the antimicrobial composition can comprise modified clay particles comprising a cosmetically effective amount of the antimicrobial compound.
Typically, the composition comprises from 0.01 to 10 wt%, more preferably from 0.01 to 5 wt%, of the modified particles (i.e., particles comprising at least one antimicrobial compound), based on the total weight of the composition. Preferably, the antimicrobial compound is CPC, and thus, the particles are CPC-clay particles.
Polymer and method of making same
The polymer is one or more copolymers selected from the group consisting of
(i) Copolymers of styrene sulfonic acid and maleic acid; (ii) polyethylene succinate; (iii) polyethylene adipate; (iv) a phosphinocarboxylic acid copolymer; or (v) a carboxylate sulfonate terpolymer.
A preferred polymer for the copolymer of styrene sulphonic acid and maleic acid of class (i) is the sodium salt of poly (4-styrenesulphonic acid-co-maleic acid). The compound or acid form thereof has the following structure:
it is available under CAS number 68037-40-1.
The polymer of polyethylene succinate of class (ii) has the structure given below:
it is available under CAS number 25569-53-3.
The polymer of polyethylene adipate of class (iii) has the structure given below:
it is available under CAS number 24938-37-2.
The polymers of the phosphinocarboxylic acid copolymers of class (iv) have the structure given below:
it is available under CAS number 110224-99-2.
Preferred polymers of the carboxylate sulfonate terpolymer of class (v) are nonionic or anionic in nature, preferably anionic. A particularly preferred polymer of this class is the copolymer acrylic acid/N-t-butylacrylamide/2-acrylamido-2-methyl-1-propanesulfonic acid having the CAS number 7732-18-5.
Preferably, the polymer is selected from copolymers of styrene sulfonic acid and maleic acid; a phosphinocarboxylic acid copolymer; or carboxylate sulfonate terpolymers.
Preferably, the polymer is present in an amount of 0.01 to 10 wt%, more preferably 0.1 to 5 wt%, based on the weight of the composition.
In a preferred embodiment, the composition is an oral care composition. Preferably, the oral care composition is selected from the group consisting of toothpaste, dentifrice, tooth powder, topical oral gel, mouthwash, denture product, oral spray, lozenge, oral tablet, chewing gum, impregnated dental appliance, dental floss, and combinations thereof. The most preferred product is toothpaste or mouthwash.
When formulated for oral care benefits, the composition comprises an orally acceptable base. The orally acceptable base preferably comprises an abrasive, humectant, surfactant, volatile alcohol, or combination thereof. More preferred orally acceptable bases include abrasives, humectants, or mixtures thereof. The orally acceptable base comprises at least 80%, more preferably at least 90%, by weight of the composition.
The oral care compositions of the present invention may be delivered in the form of an ointment, gel, dentifrice or mouthwash. Dentifrices include forms such as toothpastes and tooth powders. The composition is most preferably in the form of a toothpaste, dentifrice or mouthwash.
The oral care compositions of the present invention preferably comprise an abrasive. Gels usually contain silica, while opaque pastes usually contain calcium-based abrasives, especially chalk. The abrasive silica used for incorporation in the composition of the present invention is preferably a silica having a low refractive index. It may be used as the sole abrasive silica or in combination with low levels of other abrasive silicas such as those according to EP 236070. The low refractive index silica used as the abrasive in the present invention is preferably one having an apparent Refractive Index (RI) in the range of 1.41 to 1.47, preferably 1.435 to 1.445, preferably heavyA mean particle size of 5 to 15mm and a BET (nitrogen) surface area of 10 to 100m2A oil absorption of about 70 to 150cm3A silica per 100g, but abrasive silicas having a lower apparent refractive index may also be used. Typical examples of suitable low refractive index abrasive silicas (e.g., RI of 1.435 to 1.445) are Tixosil 63 and 73 from Rhone Poulenc; sident 10 from Degussa; zeodent 113 from Zeofinn; zeodent 124 from Huber, Sorbosil AC 77 from Crosfield Chemicals (RI about 1.440). The amount of these silicas in the compositions of the present invention is generally from 5 to 60%, and usually from 5 to 20% by weight of the composition.
In a preferred embodiment, the composition comprises a thickening agent. Thickeners useful in the present invention include sodium carboxymethylcellulose (SCMC), hydroxyethylcellulose, methylcellulose, ethylcellulose, tragacanth, acacia, karaya gum, xanthan gum, sodium alginate, carrageenan, guar gum, carrageenan (Irish moss), starch, modified starch, silica-based thickeners including silica aerogels, magnesium aluminum silicates (e.g., Veegum), carbomers (cross-linked acrylates), and mixtures thereof.
Generally, thickening silica, sodium carboxymethylcellulose, and/or carbomers are preferred thickening agents for use in the compositions of the present invention. When carbomers are used, it is desirable to have a weight average molecular weight of at least 700,000, preferably at least 1,200,000, and most preferably at least about 2,500,000. Mixtures of carbomers may also be used in the present application.
In a particularly preferred embodiment, the carbomer is Synthalen PNC, Synthalen KP or a mixture thereof. It is described as a high molecular weight and crosslinked polyacrylic acid and can be identified by CAS number 9063-87-0. These types of materials are commercially available from suppliers such as Sigma.
In another particularly preferred embodiment, the sodium carboxymethylcellulose (SCMC) used is SCMC 9H. It is described as the sodium salt of a cellulose derivative in which a carboxymethyl group is bound to the hydroxyl group of a glucopyranose backbone monomer and can be identified by CAS number 9004-32-4. Which is available from suppliers such as Alfa chem.
Thickening silicas are particularly preferred for use in gel toothpastes.
Gel toothpastes typically contain up to 8.5% by weight thickening silica, whereas opaque toothpastes typically contain 3-4% by weight thickening silica.
When present, preferred thickening silicas include the AEROSIL T series from Degussa or the CAB-O-SIL series from Cabot, a silica gel such as the SYLODENT or SYLOX series from W.R. Grace & Co, or a precipitated silica such as ZEOTHIX 265 from J.M. Huber. Useful silica thickeners also include ZEODENT 165, ZEODENT 163 and/or 167 and ZEOFREE 153, 177 and/or 265 silicas, all available from j.m. huber company. Other preferred thickening silicas include MFIL, MFIL-P (available from Madhu Silica, India), SIDENT 22S and AEROSIL 200 (available from Evonik Industries), SYLODENT and PERKASIL thickening silicas from WR Grace & Company, and Tixosil 43 and 331 from Rhodia, synthetic finely divided fumed silicas such as those sold under the trademarks SYLOID 244, SYLOID 266 and AEROSIL D-200.
The thickener, when present, preferably comprises from 0.01 to about 10%, more preferably from 0.1 to 9%, most preferably from 1.5 to 8% by weight of the composition.
Suitable humectants are preferably used in the oral care compositions of the present invention and they include, for example, glycerin, sorbitol, propylene glycol, dipropylene glycol, diglycerin, triacetin, mineral oil, polyethylene glycol (preferably PEG-400), alkane diols such as butylene glycol and hexylene glycol, ethanol, pentylene glycol, or mixtures thereof. Glycerin, polyethylene glycol, sorbitol or mixtures thereof are preferred humectants, the most preferred being glycerin (also known as glycerol) and sorbitol.
The humectant may be present at 10-90% by weight of the oral care composition. More preferably, the humectant constitutes from 25 to 80%, most preferably from 45 to 70%, by weight of the composition, based on the total weight of the composition and including all ranges subsumed therein.
Preferably, the oral care composition comprises a surfactant. When formulated as a toothpaste, the composition preferably comprises 0.01 to 20% by weight of the total composition of surfactant. Preferably, the composition comprises at least 0.01%, more preferably at least 0.1% and most preferably from 0.5 to 7% by weight of the composition of surfactant. Suitable surfactants include anionic surfactants such as sodium, magnesium, ammonium or ethanolamine salts of C8 to C18 alkyl sulfates (e.g., sodium lauryl sulfate), sodium, magnesium, ammonium or ethanolamine salts of C8 to C18 alkyl sulfosuccinates (e.g., sodium dioctyl sulfosuccinate), sodium, magnesium, ammonium or ethanolamine salts of C8 to C18 alkyl sulfoacetates (e.g., sodium lauryl sulfoacetate), sodium, magnesium, ammonium or ethanolamine salts of C8 to C18 alkyl sarcosines (e.g., sodium lauryl sarcosinate), sodium, magnesium, ammonium or ethanolamine salts of C8 to C18 alkyl phosphates (which may optionally contain up to 10 ethylene oxide and/or propylene oxide units) and sulfated monoglycerides. More preferably, the surfactant comprises or is an anionic surfactant. Preferred anionic surfactants are sodium lauryl sulfate and/or sodium dodecylbenzenesulfonate. Most preferably, the surfactant is sodium lauryl sulfate.
Other suitable surfactants include nonionic surfactants such as optionally polyethoxylated sorbitan esters of fatty acids, ethoxylated fatty acids, esters of polyethylene glycol, ethoxylates of fatty acid mono-and diglycerides, and ethylene oxide/propylene oxide block polymers. Other suitable surfactants include amphoteric surfactants such as betaines or sultaines. Mixtures of any of the above materials may also be used. The most preferred surfactants are alkali metal alkyl sulfates or betaines.
Water may preferably represent from 5 to 95%, in particular from 10 to 75%, especially from 10 to 60%, even more preferably from 10 to 45% by weight of the total composition.
When the oral care composition of the present invention is a toothpaste or gel, the viscosity is typically about 30,000-.
The oral care compositions of the present invention may contain various other ingredients commonly used in the art to enhance physical properties and performance. These ingredients include antimicrobial agents, anticaries agents, plaque buffering agents, fluoride sources, vitamins, plant extracts, desensitizing agents, anticalculus agents, biomolecules, flavoring agents, proteinaceous materials, preservatives, opacifying agents, coloring agents, pH adjusters, sweeteners, particulate abrasive materials, polymers, buffers and salts to buffer the pH and ionic strength of the composition, and mixtures thereof. These ingredients typically and collectively comprise less than 20%, preferably from 0.0 to 15%, and most preferably from 0.01 to 12% by weight of the composition, including all ranges subsumed therein.
Preferably, the composition comprises one or more orally acceptable components such as abrasives, orally acceptable actives (such as Fluor), tooth whitening agents, flavorants, stabilizers, preservatives and other conventional components of oral care compositions.
Use of antimicrobial compositions
The inventors have found that the antimicrobial composition according to the invention has improved antimicrobial activity. Thus, the antimicrobial composition may be used in cosmetic (non-therapeutic) or therapeutic applications.
a) Therapeutic uses
In one aspect, the composition according to the invention is for use in the prevention or treatment of a disease in a mammal. Disease as used herein refers to a disease caused by microorganisms on the body surface (skin, nails, mucous membranes, etc.). In one embodiment, the disease is a dermatological disease, such as those caused by propionibacterium (Propionibacteria spp.), corynebacterium (corynebacterium spp.), actinomycete (actinomycetes), staphylococcus (staphylococcus spp.), lactobacillus (staphylococcus epidermidis), clostridium (clostridium), proteobacteria (proteobacteria), flavobacterales (flavobacterales), bacterales (bacteriodes), Malassezia (Malassezia) yeasts (e.g. Malassezia furfur (Malassezia furfur) and Malassezia), and the like, selected from the group consisting of acne, eczema, or bacterial or fungal infection of the scalp, nails, or skin.
Preferably, the use is for the prevention or treatment of oral diseases. Preferred oral diseases are selected from the group consisting of caries, dental calculus, dental plaque, gum disease and combinations thereof, for example diseases caused by actinomycetes, streptococcus such as streptococcus mutans (s.mutans) and streptococcus sobrinus (s.sobrinus), Lactobacillus such as Lactobacillus acidophilus (Lactobacillus acidophilus), Nocardia (Nocardia spp), haemophilus, cellulophaga, veyonia, neisseria, clostridium such as Fusobacterium nucleatum, treponema, tannorella (tannorella spp) such as Fusobacterium fuscesensium, porphyromonas gingivalis, actinosynechococcus actinomyces and the like.
In another aspect, the antimicrobial compositions of the present invention are used to remove oral biofilms in mammalian subjects.
b) Cosmetic/non-therapeutic use
The present invention provides cosmetic use of an antimicrobial composition on a body surface such as skin, teeth, scalp, mucous membranes (gums), tongue, and the like. The present inventors have found improved antimicrobial activity against microorganisms that are commonly found on such body surfaces and that may impair the physical appearance (e.g. tooth yellowing) or body taste, particularly oral malodor. Preferably, the antimicrobial composition is for cosmetic use in the prevention or treatment of halitosis caused by microorganisms in the oral cavity.
Thus, in another aspect, the present invention relates to a non-therapeutic method of treating the skin or oral cavity of a mammal comprising the step of contacting the skin or oral cavity of the mammal with an antimicrobial composition of the present invention.
In another aspect, the present invention relates to the use of the antimicrobial composition of the present invention for reducing body malodor, preferably oral malodor and/or for reducing oral biofilm formation and/or for reducing dental discoloration in a mammal.
Detailed Description
Examples
Example 1 preparation of modified Clay particles
To prepare the modified clay particles comprising the antimicrobial compound according to the invention, the following process was used:
5g of kaolinite (Superstone 90, EICL) were placed in 500ml of 0.1N HCl (Merck) solution and sonicated for 30 minutes. The pH was then raised to 9 by dropwise addition of NaOH (Merck) solution. 10g of CPC were added to it and the suspension was stirred on a magnetic stirrer (Spinpot) for 6 hours while maintaining the temperature of the solution at 75-80 ℃. The suspension was then washed with water about 10 times to remove excess CPC and finally with ethanol (Les Alcools De Commerce). The clay was then dried in a hot air oven.
To confirm the attachment of CPC to clay after reaction FTIR spectroscopy was used. The instrument used was a Perkin Elmer instrument, a Spectrum One FT-IR spectrometer. Powder (diffuse reflection) technique was used for this measurement. The clay used as control and the clay after the reaction of the invention were ground in a mortar and pestle with 50% w/w of KBr and then the IR was measured on these powders. The infrared spectrum of the clay after the reaction was compared with that of the pure clay. The reacted clay was found to be 2926cm-1、2855cm-1、1487cm-1And 1466cm-1A new peak was observed. 2926cm-1And 2855cm-1The peak at (A) is due to C-C stretching of the alkyl chain of CPC, while 1487cm-1And 1466cm-1The peaks at (a) are due to the ring carbon and nitrogen of CPC.
EXAMPLE 2 antimicrobial Activity of active Material
The antimicrobial activity of the composition according to the invention was compared with the antimicrobial activity of a composition comprising only modified clay particles comprising the antimicrobial compound ("CPC", prepared as in example 1) or only the copolymer. The salivary flora and the actives (according to table 1 below) were incubated together overnight and the biofilm was stained with crystal violet at the end of the incubation. Detailed protocol is as follows
Treatment and biofilm formation
Samples of morning saliva were collected before brushing 4-5 people, pooled together and washed twice in saline. The absorbance of the ultrafiltrated tryptone yeast extract broth (2% sucrose) was set to 0.2OD620nm and used for the experiments mentioned in the further steps. 2ml of the fixed culture was added to 24/12 well plates, and different concentrations of the test active were added to each well. The plates were incubated anaerobically at 37 ℃ overnight.
Dyeing protocol
At the end of the overnight incubation, the plates were poured into biohazard bags to remove all planktonic bacteria. The plate was then rinsed in a pan of water, and the water was then poured over the pan. This step is performed once to remove loosely adhered biofilm. The plate was then placed on a blotter/paper towel on a countertop. All test wells were stained with 1ml of 1% crystal violet stain (CV) for 10 minutes. This step is performed using a pipette. The plate was poured into a biohazard bag to remove all staining agents. The plate was then rinsed in a pan of water and the water was poured onto the pan. This step was carried out three times in succession in three separate water pans. (each tray procedure was repeated 3-9 flushes total). The countertop was covered with more blotter/paper towel and the board was bumped against the countertop until all holes were free of any liquid. This step was performed to ensure that only the remaining CV bound to the biofilm at the bottom of the well. The plate was placed on a bench top at room temperature (23. + -. 2 ℃ C.) with the plate facing up until it was completely dry. To the test wells 1ml of 33% glacial acetic acid was added to dissolve the biofilm-bound CV stain. The acetic acid was allowed to stand for 10 minutes. The mixture of acetic acid and CV was aspirated up and down the wells.
10 μ l of the above solution was transferred to 90 μ l of 33% acetic acid in wells of a flat-bottomed 96-well plate. The solution was mixed well and the absorbance was measured at 540 nm. All actives tested were performed in duplicate.
The percentage of biofilm obtained for each sample is summarized in the following table
TABLE 1
| Examples | Composition comprising a metal oxide and a metal oxide | % biofilm | Standard deviation of rotation |
| 2A | Substrate | 99.97 | 0.05 |
| 2B | 2% PSS-Co maleic acid1 | 27.5 | 3.3 |
| 2C | 1.5% CPC-Clay | 99.0 | 12 |
| 2D | 2% PSS Co-maleic acid + 1.5% CPC-Clay2 | 5.3 | 0.2 |
| 2E | 2％ConWTP31003 | 32.2 | 2.1 |
| 2F | 2% ConWTP3100+ 1.5% CPC-Clay | 2.6 | 0.2 |
| 2G | 2% phosphinocarboxylic acid co-polymerizationPolymer and method of producing the same | 40.5 | 12.2 |
| 2H | 2% Phosphino-Carboxylic acid copolymer + 1.5% CPC-Clay | 2.2 | 0.2 |
1PSS-Co maleic acid is a copolymer of styrene sulfonic acid and maleic acid
2CPC Clay is a modified clay particle prepared as in example 1
3ConWTP3100 is a carboxylate sulfonate terpolymer
The data in Table-1 above show that the compositions comprising modified clays and copolymers (examples 2D, 2F and 2H) provide synergistic anti-biofilm efficacy over the individual components (examples 2B, 2C, 2E and 2G).
Claims (13)
1. An antimicrobial composition comprising:
a) modified clay particles comprising an antimicrobial compound, the modified clay particles comprising:
(i) asymmetric 1: 1 or 2: 1 clay particles comprising alternating tetrahedral and octahedral sheets that terminate in a tetrahedral sheet at one external surface plane and an octahedral sheet at another external surface plane, and
(ii) at least one orally acceptable antimicrobial compound attached to coordinating cations on the outer surface plane of the clay particles; and
b) a polymer selected from (i) a copolymer of styrene sulfonic acid and maleic acid; (ii) polyethylene succinate; (iii) polyethylene adipate; (iv) a phosphinocarboxylic acid copolymer; or (v) a carboxylate sulfonate terpolymer; and is
Wherein the antimicrobial compound is a quaternary ammonium material.
2. The composition of claim 1, wherein the quaternary ammonium material is selected from the group consisting of cetylpyridinium chloride (CPC), cetyltrimethylammonium chloride (CTAC), cetyltrimethylammonium bromide (CTAB), benzalkonium chloride (BKC), benzethonium chloride, cetrimide, and polyhexamethylene BH.
3. A composition according to claim 1 or 2 wherein the antimicrobial compound is linked to coordinating cations on the external surface of the octahedral surface plane.
4. The composition according to any one of the preceding claims, wherein the weight ratio clay: antimicrobial compound is between 1: 0.001 and 1: 0.1.
5. A composition according to any preceding claim, wherein the quaternary ammonium material is cetylpyridinium chloride (CPC).
6. A composition according to any preceding claim, wherein the modified clay particles are from 0.01 to 10% by weight of the composition.
7. The composition of any of the preceding claims, wherein the polymer is selected from the group consisting of (i) a copolymer of styrene sulfonic acid and maleic acid; (ii) a phosphinocarboxylic acid copolymer; or (iii) a carboxylate sulfonate terpolymer.
8. A composition according to any preceding claim, wherein the polymer is present in an amount of from 0.01 to 10% by weight of the composition.
9. The composition of any one of the preceding claims, comprised in an oral care product selected from the group consisting of toothpaste, dentifrice, tooth powder, topical oral gel, mouthwash, denture product, oral spray, lozenge, oral tablet, chewing gum, impregnated dental implement, dental floss, and combinations thereof.
10. The composition of any one of the preceding claims for use in the prevention or treatment of a disease in a mammal, preferably for use in the prevention or treatment of an oral disease selected from the group comprising dental caries, dental calculus, dental plaque, gum disease and combinations thereof.
11. A composition according to any one of claims 1 to 9 for use in removing oral biofilm from a mammalian subject.
12. A non-therapeutic method of treating mammalian skin and/or oral cavity comprising the step of contacting the skin and/or oral cavity of a mammal with an antimicrobial composition according to any of the preceding claims 1-9.
13. Use of a composition according to any one of claims 1 to 9 for reducing body malodor, preferably oral malodor, and/or for reducing oral biofilm formation and/or for reducing dental discoloration in a mammal.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19212150.7 | 2019-11-28 | ||
| EP19212150 | 2019-11-28 | ||
| PCT/EP2020/080118 WO2021104780A1 (en) | 2019-11-28 | 2020-10-27 | Antimicrobial compositions comprising modified clay and copolymers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114746063A true CN114746063A (en) | 2022-07-12 |
Family
ID=68731855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080082792.5A Pending CN114746063A (en) | 2019-11-28 | 2020-10-27 | Antimicrobial compositions comprising modified clays and copolymers |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP4065065A1 (en) |
| CN (1) | CN114746063A (en) |
| BR (1) | BR112022007844A2 (en) |
| CL (1) | CL2022001361A1 (en) |
| WO (1) | WO2021104780A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11701317B2 (en) | 2021-03-24 | 2023-07-18 | L'oreal | Cosmetic compositions for removing makeup and methods thereof |
| FR3124948A1 (en) * | 2021-07-09 | 2023-01-13 | L'oreal | Cosmetic compositions for removing make-up and corresponding processes |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4842847A (en) * | 1987-12-21 | 1989-06-27 | The B. F. Goodrich Company | Dental calculus inhibiting compositions |
| US20030139478A1 (en) * | 2001-12-20 | 2003-07-24 | Harper D Scott | Non-halogenated hydroxyalkyl-substituted phenol compounds, antimicrobial compositions containing the same, and methods of using the same |
| CN102575205A (en) * | 2009-09-24 | 2012-07-11 | 荷兰联合利华有限公司 | An antimicrobial particle and a process for preparing the same |
| EP2476406A2 (en) * | 2010-12-08 | 2012-07-18 | Henkel AG & Co. KGaA | Oral and tooth care and cleaning agents with improved antibacterial effect II |
| CN104869976A (en) * | 2012-12-27 | 2015-08-26 | 荷兰联合利华有限公司 | Oral care composition having an adduct of clay and antibacterial agent |
| CN108430436A (en) * | 2015-12-17 | 2018-08-21 | 高露洁-棕榄公司 | Include the oral care composition of at least one phosphate/acrylate copolymer and at least one cationic active constituent |
| US20180338945A1 (en) * | 2015-10-31 | 2018-11-29 | Dermalink Technologies, Inc. | Skin adhesives, antimicrobial compositions, articles, and methods for the use thereof |
| JP2018193500A (en) * | 2017-05-19 | 2018-12-06 | 株式会社日本触媒 | Biodegradable resin particle |
| WO2019034387A1 (en) * | 2017-08-17 | 2019-02-21 | Unilever N.V. | Method of promoting remineralisation of teeth |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8604985D0 (en) | 1986-02-28 | 1986-04-09 | Unilever Plc | Precipitated silicas |
| US4892725A (en) | 1988-05-09 | 1990-01-09 | The B. F. Goodrich Company | Tartar inhibition on teeth |
| US5202112A (en) | 1991-08-01 | 1993-04-13 | Colgate-Palmolive Company | Viscoelastic dentifrice composition |
| US20120321568A1 (en) | 2011-06-20 | 2012-12-20 | Denis Alfred Gonzales | Liquid cleaning and/or cleansing composition |
-
2020
- 2020-10-27 CN CN202080082792.5A patent/CN114746063A/en active Pending
- 2020-10-27 WO PCT/EP2020/080118 patent/WO2021104780A1/en active Search and Examination
- 2020-10-27 EP EP20796586.4A patent/EP4065065A1/en active Pending
- 2020-10-27 BR BR112022007844A patent/BR112022007844A2/en unknown
-
2022
- 2022-05-24 CL CL2022001361A patent/CL2022001361A1/en unknown
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4842847A (en) * | 1987-12-21 | 1989-06-27 | The B. F. Goodrich Company | Dental calculus inhibiting compositions |
| US20030139478A1 (en) * | 2001-12-20 | 2003-07-24 | Harper D Scott | Non-halogenated hydroxyalkyl-substituted phenol compounds, antimicrobial compositions containing the same, and methods of using the same |
| CN102575205A (en) * | 2009-09-24 | 2012-07-11 | 荷兰联合利华有限公司 | An antimicrobial particle and a process for preparing the same |
| EP2476406A2 (en) * | 2010-12-08 | 2012-07-18 | Henkel AG & Co. KGaA | Oral and tooth care and cleaning agents with improved antibacterial effect II |
| CN104869976A (en) * | 2012-12-27 | 2015-08-26 | 荷兰联合利华有限公司 | Oral care composition having an adduct of clay and antibacterial agent |
| US20180338945A1 (en) * | 2015-10-31 | 2018-11-29 | Dermalink Technologies, Inc. | Skin adhesives, antimicrobial compositions, articles, and methods for the use thereof |
| CN108430436A (en) * | 2015-12-17 | 2018-08-21 | 高露洁-棕榄公司 | Include the oral care composition of at least one phosphate/acrylate copolymer and at least one cationic active constituent |
| JP2018193500A (en) * | 2017-05-19 | 2018-12-06 | 株式会社日本触媒 | Biodegradable resin particle |
| WO2019034387A1 (en) * | 2017-08-17 | 2019-02-21 | Unilever N.V. | Method of promoting remineralisation of teeth |
| CN110997071A (en) * | 2017-08-17 | 2020-04-10 | 荷兰联合利华有限公司 | Method for promoting tooth remineralization |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022007844A2 (en) | 2022-07-05 |
| EP4065065A1 (en) | 2022-10-05 |
| WO2021104780A1 (en) | 2021-06-03 |
| CL2022001361A1 (en) | 2023-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6348509B2 (en) | Zinc amino acid halide complexes with cysteine | |
| CA2669019C (en) | Oral care compositions containing combinations of anti-bacterial and host-response modulating agents | |
| CN1909875B (en) | Oral care compositions comprising increased bioavailable levels of quaternary ammonium antimicrobials | |
| RU2670445C2 (en) | Dentifrice comprising zinc - amino acid complex and phosphates | |
| AU2008349845B2 (en) | Oral care regimen | |
| TWI434702B (en) | Abrasive system for oral care compositions | |
| EP3082712B1 (en) | Oral care compositions and methods | |
| CN114746063A (en) | Antimicrobial compositions comprising modified clays and copolymers | |
| WO2021259748A1 (en) | Compositions comprising zinc and antimicrobial agent | |
| EP3082713A1 (en) | Oral care compositions and methods | |
| AU2013408263B2 (en) | Oral care compositions and methods | |
| US20090202452A1 (en) | Oral care regimen | |
| CN113260347B (en) | Antimicrobial compositions comprising modified clay and bisphenol | |
| CN113226262B (en) | Antibacterial composition comprising modified clay and copolymer | |
| AU2009343753A1 (en) | Desensitizing dentifrice exhibiting dental tissue antibacterial agent uptake | |
| EP0414788A1 (en) | Mouthcare-products. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |